Transforming growth factor β receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment

Clinical Cancer Research

Volumn 10, Issue 22, 2004, Pages 7540-7546

  Hayashi, Toshiaki ^a   Hideshima, Teru ^a   Nguyen, Aaron N ^b   Munoz, Olivier ^b   Podar, Klaus ^a   Hamasaki, Makoto ^a   Ishitsuka, Kenji ^a   Yasui, Hiroshi ^a   Richardson, Paul ^a   Chakravarty, Sarvajit ^b   Murphy, Alison ^b   Chauhan, Dharminder ^a   Higgins, Linda S ^b   Anderson, Kenneth C ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SCIOS INC   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 6; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR I KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR I KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BONE MARROW CELL; CELL ADHESION; CELL PROLIFERATION; CYTOKINE RELEASE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; STROMA CELL; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; BONE MARROW; BONE MARROW CELLS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; DOWN-REGULATION; ENZYME INHIBITORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; INTERLEUKIN-6; LYMPHOCYTES; MICROSCOPY, FLUORESCENCE; MULTIPLE MYELOMA; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 9344245148     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0632     Document Type: Article

References (32)

1. kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000;19:4319-27.
2. Shain KH, Landowski TH, Dalton WS. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 2002;168:2544-53.
3. Ogata A, Chauhan D, Teoh G, et al. Interleukin-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997;159:2212-21.
4. Hideshima T, Chauhan D, Teoh G, et al. Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clin Cancer Res 2000;6:1180-9.
5. Chauhan D, Hideshima T, Rosen S, et al. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem 2001;276:24453-6.
6. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001;20:5991-6000.
7. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428-35.
8. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5.
9. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000;95:2630-6.
10. Hayashi T, Hideshima T, Akiyama M, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2003;102:1435-42.
11. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-23.
12. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50.
13. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (Baltimore) 2001;15:1950-61.
14. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7.
15. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
16. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-b: pleiotropic role in the regulation of hematopoiesis. Blood 2000;96:2022-36.
17. Derynck R, Akhurst RJ, Balmain A. TGF-b signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
18. Gorelik L, Flavell RA. Transforming growth factor-b in T-cell biology. Nat Rev Immunol 2002;2:46-53.
19. Urashima M, Ogata A, Chauhan D, et al. Transforming growth factor-b1: differential effects on multiple myeloma versus normal B cells. Blood 1996;87:1928-38.
20. Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-b1 and interleukin-10. Blood 2001;98:2992-8.
21. Liu Y-W, Siedner M, Tran T-T, et al. Inhibition of TGF-b receptor kinase activity prevents Smad signaling in in vitro and in vivo models of lung injury. In: American Thoracic Society 99th International Conference; 2003. Abstract 2812.
22. Hayashi T, Treon SP, Hideshima T, et al. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol 2003;121:592-6.
23. Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002;1:851-60.
24. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-37.
25. Hayashi T, Hideshima T, Anderson KC. Novel therapies for multiple myeloma. Br J Haematol 2003;120:10-7.
26. Park JI, Lee MG, Cho K, et al. Transforming growth factor-b1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kB, JNK, and Ras signaling pathways. Oncogene 2003;22:4314-32.
27. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (Lond) 1998;394:485-90.
28. Shih SC, Claffey KP. Role of AP-1 and HIF-1 transcription factors in TGF-b activation of VEGF expression. Growth Factors 2001;19:19-34.
29. Broek IV, Asosingh K, Vanderkerken K, et al. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 2003;88:855-62.
30. Kim SJ, Letterio J. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. Leukemia (Baltimore) 2003;17:1731-7.
31. Derynck R, Zang YE. Smad-dependent and Smad-independent pathways in TGF-b family signaling. Nature (Lond) 2003;425:577-84.
32. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-67.